Predicting response to CGRP-monoclonal antibodies in patients with migraine in Japan: a single-centre retrospective observational study

• Published in: Journal of headache and pain Vol. 24; no. 1; pp. 23 - 10
• Main Authors: Ihara, Keiko, Ohtani, Seiya, Watanabe, Narumi, Takahashi, Nobuyuki, Miyazaki, Naoki, Ishizuchi, Kei, Hori, Satoko, Takemura, Ryo, Nakahara, Jin, Takizawa, Tsubasa
• Format: Journal Article
• Language: English
• Published: Milan Springer Milan 09.03.2023; Springer Nature B.V; BMC
• Subjects: Antibodies, Monoclonal - pharmacology; Antibodies, Monoclonal - therapeutic use; Calcitonin; Calcitonin gene-related peptide; Calcitonin Gene-Related Peptide - therapeutic use; CGRPmAbs; Double-Blind Method; Erenumab; Galcanezumab; Headache; Headache - drug therapy; Humans; Internal Medicine; Japan; Medicine; Medicine & Public Health; Migraine; Migraine Disorders - drug therapy; Monoclonal antibodies; Neurology; Observational studies; Pain Medicine; Patients; Real-word evidence of emerging therapies in headache; Statistical analysis; Treatment Outcome; Japan; Headache; Fremanezumab; Migraine; Japan; CGRPmAbs; Erenumab; Galcanezumab

Background Anti-calcitonin gene-related peptide monoclonal antibodies (CGRPmAbs) are a favourable option for patients with migraine who experience distressful headache disability and fail to respond to traditional preventive treatment options. However, since CGRPmAb has been available for only 2 yea...